Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR By Ogkologos - July 28, 2025 571 0 Facebook Twitter Google+ Pinterest WhatsApp Final results from the IMpassion031 study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR ACS’s Updated Cervical Cancer Screening Guidelines Explained September 18, 2020 24% of Breast Cancers Diagnosed Between Mammograms Could Have Been Detected... May 10, 2021 Cancer in Lymph Nodes May Help Tumors Spread by Enlisting Immune... May 27, 2022 How Can I Get the Latest Cancer Drug? October 14, 2020 Load more HOT NEWS How Clinical Trials Can Lead to Life-Saving Treatment: The TAPUR Trial... Majority of Patients With Cancer Are Willing To Be Vaccinated Against... NF1 Associated with More Cancer Types Than Previously Known Modest Population-Level Increases in Survival Observed After Implementation of Immune Checkpoint...
